Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents

Míreanna Comhchosúla

• Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
  le: Wardell, Suzanne E., et al.
  Foilsithe: (2019)
• Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
  le: Wardell, Suzanne E., et al.
  Foilsithe: (2019)
• The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
  le: Wardell, Suzanne E., et al.
  Foilsithe: (2011)
• The Antiestrogens Tamoxifen and Fulvestrant Abolish Estrogenic Impacts of 17α-ethinylestradiol on Male Calling Behavior of Xenopus laevis
  le: Hoffmann, Frauke, et al.
  Foilsithe: (2012)
• A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses
  le: Clusan, Léa, et al.
  Foilsithe: (2021)